Point/counterpoint

April 13, 2025 Check out STAT+

Sponsored By

By Torie Bosch First Opinion editor

Happy Sunday! Recently, I published a lovely essay by a physician and novelist about why she doesn't want to use an AI scribe to help with patient notes. On Wednesday, I published the counterpoint: A doctor who was initially skeptical about AI scribes wrote about how she became convinced. She writes that the AI scribe allows her to look at her patients directly instead of focusing on the screen. I'd love to do more of these point/counterpoint essays and debates. What topics should these features take on? What about writers? Let me know your thoughts. Recommendation of the week: I'm not saying "Death of a Unicorn" is a good movie, exactly — but once it's available on streaming, I think it will be worth the watch, if only for Téa Leoni's performance as the wife of a pharmaceutical magnate and for Will Poulter's performance as her son. The two of them have a darkly funny view of the pharma industry.

---

---

Adobe Personal choice has been weaponized to undermine public health How did we get to this place where public health is the enemy, that opting out is strength? By MeiLan Han Other countries must step up to fill the void of USAID No country can fill the void left by USAID. But the rest of the world's wealthy nations must work together to take its place. By Arjun Sharma The wellness industry is killing animals, spreading disease, and fueling the next pandemic Wellness misinformation isn't just rampant in human health — it's deeply embedded in veterinary health, too. By Andrea Love Kayana Szymczak for STAT STAT+ | AI scribe technology lets me focus on my patients, not a screen Once physician Iyesatta Massaquoi Emeli began using an ambient-listening AI scribe to capture notes, she became a true believer. By Iyesatta Massaquoi Emeli The invisibility of good public health work Two county health department leaders discuss how chaos in Washington is hurting their attempts to fight both infectious and chronic disease. By Torie Bosch The Trump administration should rescind the NIH 'access planning' rule The rule requiring anyone seeking to license some NIH patents to explain how the product will be available to underserved groups is noble but misguided. By Jon Soderstrom Adobe Don't overlook the continued threat of cuts to universities' indirect research costs The issue of reimbursement for facilities and administrative costs is far from settled — and similar cuts may be coming down the pike. By Barbara R. Snyder  STAT+ | BridgeBio CEO: Congress must renew a popular, bipartisan FDA program benefiting sick kids BridgeBio CEO calls on Congress to renew a program that aids rare disease drug development that has saved thousands of lives at no cost to taxpayers. By Neil Kumar

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying First Opinion? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser